Cargando…
Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
BACKGROUND: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the mucosal barrier in response to viral infection and/or cigarette smoke. METHODS:...
Autores principales: | Heijink, I. H., Jonker, M. R., de Vries, M., van Oosterhout, A. J. M., Telenga, E., ten Hacken, N. H. T., Postma, D. S., van den Berge, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704248/ https://www.ncbi.nlm.nih.gov/pubmed/26739349 http://dx.doi.org/10.1186/s12931-015-0318-z |
Ejemplares similares
-
Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018) -
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007) -
Airway wall thickness on HRCT scans decreases with age and increases with smoking
por: Telenga, Eef D., et al.
Publicado: (2017) -
Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019) -
Efficacy of intranasal fluticasone propionate and budesonide in management of allergic rhinitis—a prospective comparative study
por: Shankari, P. Kiruba, et al.
Publicado: (2021)